☆ 3.9 Article

EV-103 Study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

EUROPEAN UROLOGY SUPPLEMENTS (2018)

Get Full Text
Add to Collection

Journal

EUROPEAN UROLOGY SUPPLEMENTS
Volume 17, Issue 2, Pages e1151

Publisher

Elsevier BV
DOI: 10.1016/s1569-9056(18)31639-7

Keywords

-

Categories

-

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.